Astra Zeneca chases biosimilar Avastin with Fujifilm Kyowa Kirin Biologics

July 29, 2015 7:48 AM

AstraZeneca is dipping its toe in the biosimilars market, as a way to make future cancer drugs more affordable, by linking with a Japanese group to develop a biosimilar of blockbuster medicine Avastin, Reuters reports.

Its new 50/50 joint venture with Fujifilm Kyowa Kirin Biologics (FKB) will work on a biosimilar version of Avastin, which is currently used in a range of solid tumors and also has potential to be given alongside new immunotherapy treatments.

FKB — itself a tie-up between Fujifilm and Kyowa Hakko Kirin — commenced a Phase I clinical trial of its copy of Avastin, called FKB238, in Europe last November.

Under the terms of the agreement, FKB will transfer the rights to FKB238 to the new joint venture and will receive a lump-sum payment of $45 million in return.

An AstraZeneca spokeswoman said the move did not reflect a shift away from the British company’s focus on innovative products but rather was a way to develop a product that could be used in affordable drug cocktails.

“This supports our combination-focused strategy in oncology to help explore potential new treatment options, whilst keeping the cost of new therapies low enough to enable access for patients and payers,” she said.

Immunotherapy drugs, which harness the immune system to fight tumors, represent a significant advance in cancer treatment but many experts believe their greatest promise lies in combining them with drugs that work in different ways. Roche, the world’s biggest maker of cancer drugs, is already exploring such combinations using Avastin.

Roche said on Thursday it expected the first biosimilar copies of its cancer medicines Rituxan and Herceptin to hit the market in late 2017, with competition to Avastin coming later, since it has longer patent protection.

Source: Reuters


Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!